Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: Implications for pandemrix-associated narcolepsy risk

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Vaarala, Outi ^a   Vuorela, Arja ^a   Partinen, Markku ^b   Baumann, Marc ^c   Freitag, Tobias L ^b,c   Meri, Seppo ^a   Saavalainen, Päivi ^b,c   Jauhiainen, Matti ^a   Soliymani, Rabah ^c   Kirjavainen, Turkka ^d   Olsen, Päivi ^e   Saarenpää Heikkilä, Outi ^f   Rouvinen, Juha ^g   Roivainen, Merja ^a   Nohynek, Hanna ^a   Jokinen, Jukka ^a   Julkunen, Ilkka ^a,h   Kilpi, Terhi ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; HLA DQB1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; VIRUS NUCLEOPROTEIN; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN; IMMUNOGLOBULIN G; VIRUS ANTIGEN;

ADOLESCENT; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CATAPLEXY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; FEMALE; GEL ELECTROPHORESIS; GENOTYPE; HEMAGGLUTINATION INHIBITION; HETEROZYGOSITY; HLA SYSTEM; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A (H1N1); MALE; MASS SPECTROMETRY; MOUSE; NARCOLEPSY; NONHUMAN; OPTICAL DENSITY; PANDEMIC INFLUENZA; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; ULTRACENTRIFUGATION; ALLELE; ANIMAL; ANTIBODY PRODUCTION; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; NONOBESE DIABETIC MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; PRESCHOOL CHILD;

MUS MUSCULUS;

ADOLESCENT; ALLELES; ANIMALS; ANTIBODY FORMATION; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; HLA-DQ BETA-CHAINS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE, INBRED NOD; NARCOLEPSY; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84918802053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114361     Document Type: Article

References (36)

1. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, et al. (2014) Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 13: 600-6132.
2. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, et al. (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 7: e33536.
3. Läkemedelsverket website. Available: http://www.lakemedelsverket.se/english/All-news/NYHETER-2011/Report-from-an-epidemiological-study-in-Sweden-on-vaccination-with-Pandemrix-and-narcolepsy-/ Accessed 2014 November 21.
4. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, et al. (2013) Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med14: 867-71.
5. Health Protection Surveillance Centre website. Available: http://www.hpsc.ie/A-Z/Respiratory/Influenza/PandemicInfluenza/PandemicInfluenzaH1N12009/Vaccination/File,13379,en.pdf. Accessed 2014 November 21.
6. ANSM website. Available: http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Vaccins-pandemiques-grippe-A-H1N1-et-narcolepsie-Resultats-de-l-etude-europeenne-et-de-l-etude-cas-temoins-francaise-Point-d-information. Accessed 2014 November 21.
7. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, et al. (2013) Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346: f794.
8. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, et al. (2014) Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med 275: 172-90.
9. THL website. Available: http://www4.thl.fi/en-US/web/en/pressrelease?id5 33516. Accessed 2014 November 21.
10. Hor H, Kutalik Z, Dauvilliers Y, Valsesia A, Lammers GJ, et al. (2010) Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 42: 786-9.
11. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, et al. (2009) Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41: 708-11.
12. Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, et al. (2011) Common variants in P2RY11 are associated with narcolepsy. Nat Genet 43: 66-71.
13. Faraco J, Lin L, Kornum BR, Kenny EE, Trynka G, et al. (2013) ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 9: e1003270.
14. Billiard M, Laaberki C, Reygrobellet C, Seignalet J, Brissaud L, et al. (1989) Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 18: 201.
15. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, et al. (2009) Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 32: 979-83.
16. Han F, Lin L, Warby SC, Faraco J, Li J, et al. (2011) Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 70: 410-417.
17. Han F, Lin L, Li J, Dong XS, Mignot E (2012) Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol 73: 560.
18. De la Herrán-Arita AK, Kornum BR, Mahlios J, Jiang W, Lin L, et al. (2013) CD4+ Tcell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med. 5: 216ra176.
19. European Medicines Agency. Assessment report of 25 July 2013, EMA/691037/2013 by the Committee for Medicinal Products for Human Use (CHMP):International non-proprietary name: pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) A/California/7/2009 (H1N1)v like strain (x-179a)". Procedure No.: EMEA/H/C/000832/II/0061. European Medicines Agency website. Available: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Assessment-Report---Variation/human/000832/WC500157550.pdf. Accessed 2014 November 21.
20. Health Canada website. Available: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/pdf/prodpharma/legislation/interimorders-arretesurgence/prodinfo-vaccin-eng.pdf.Accessed 2001 November 21.
21. European Medicines Agency website. Available: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000832/WC500038121.pdf. Accessed 2014 November 21.
22. European Medicines Agency. Assessment report Immunological differences of pandemic vaccines (review of hypothesis on Pandemrix and development of narcolepsy). European Medicines Agency website. Available: http://www.ema.europa.eu/docs/en-GB/document-library/Report/2012/11/WC500134716.pdf. Accessed 2014 November 21.
23. Hayward SL, Bautista-Lopez N, Suzuki K, Atrazhev A, Dickie P, et al. (2006) CD4 T cells play major effector role and CD8 T cells initiating role in spontaneous autoimmune myocarditis of HLA-DQ8 transgenic IAb knockout nonobese diabetic mice. J Immunol 176: 7715-25.
24. Strengell M, Ikonen N, Ziegler T, Julkunen I (2011) Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS One 6: e25848.
25. Samoilovich E, Roivainen M, Titov LP, Hovi T (2003) Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol 71: 274-80.
26. Mikk ML, Kiviniemi M, Laine AP, Harkonen T, Veijola R, et al. (2014) The HLA-B∗39 allele increases type 1 diabetes risk conferred by HLA-DRB1∗04:04-DQB1∗03:02 and HLA-DRB1∗08-DQB1∗04 class II haplotypes. Hum Immunol 75: 65-70.
27. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-53.
28. Vikstedt R, Metso J, Hakala J, Olkkonen VM, Ehnholm C, et al. (2007) Cholesterol efflux from macrophage foam cells is enhanced by active phospholipid transfer protein through generation of two types of acceptor particles. Biochemistry 46: 11979-86.
29. Prokudina EN, Semenova N, Chumakov V, Stitz L (2008) An antigenic epitope of influenza virus nucleoprotein (NP) associated with polymeric forms of NP. Virol J 5: 37.
30. le Maire M, Champeil P, Moller JV (2000) Interaction of membrane proteins and lipids with solubilizing detergents. Biochim Biophys Acta 1508: 86-111.
31. Hermeling S, Schellekens H, Crommelin DJA, Jiskoot W (2003) Micelle-associated protein in epopoetin formulations: a risk factor for immunogenicity? Pharmac Res 20: 1903-1907.
32. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, Hublin C, Linna M, et al. (2012) Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 7: e33723.
33. Melén K, Partinen M, Tynell J, Sillanpää M, Himanen S-L, et al. (2013) No Serological Evidence of Influenza A H1N1pdm09 Virus Infection as a Contributing Factor for Childhood Narcolepsy After Pandemrix Vaccination Campaign in Finland. PLoS ONE 8: e68402.
34. Choe YJ, Bae GR, Lee DH (2012) No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea:an ecological study. Vaccine 30: 7439-42.
35. Lind A, Ramelius A, Olsson T, Arnheim-Dahlström L, Lamb F, et al. (2014) A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010. J Autoimmun 50: 99-106.
36. Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, et al. (2011) H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31: 443-54.